Craig M Kessler
Affiliation: Georgetown University
- Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literatureE Asatiani
Hemophilia and Thrombophilia Comprehensive Care Center, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA
Haemophilia 13:685-96. 2007..Successful therapy required an individualized approach, employing multiple replacement strategies, based on the laboratory definition of the specific additional coagulation defect...
- Use of objective efficacy criteria for evaluation of von Willebrand factor/factor VIII concentratesCraig M Kessler
Division of Coagulation, Georgetown University Medical Center, Washington, District of Columbia 20007, USA
Blood Coagul Fibrinolysis 23:262-7. 2012..This new approach may be a more suitable alternative for hemostatic assessment of coagulation products in VWD patients than the currently used subjective methods...
- Consensus recommendations for the diagnosis and treatment of acquired hemophilia APeter Collins
Arthur Bloom Hemophilia centre, School of Medicine, Cardiff University, University Hospital of Wales, Cardiff, CF14 4XN, UK
BMC Res Notes 3:161. 2010..AHA usually presents to clinicians without prior experience of the disease, therefore diagnosis is frequently delayed and bleeds under treated...
- Update on liver disease in hemophilia patientsCraig M Kessler
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
Semin Hematol 43:S13-7. 2006....
- Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data?C M Kessler
Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington, DC 20057, USA
J Thromb Haemost 4:963-6. 2006
- New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrateC M Kessler
Division of Hematology and Oncology, Georgetown University Medical Center, Washington, DC 20007, USA
Curr Opin Hematol 7:408-13. 2000..This review will discuss this new medication and place into the context of coagulation inhibitor therapy...
- Diagnosis and treatment of von Willebrand disease: new perspectives and nuancesC M Kessler
Lombardi Comprehensive Cancer Center, Division of Haematology Oncology, Georgetown University Medical Center, Washington, DC, USA
Haemophilia 13:3-14. 2007
- Recent developments in topical thrombinsCraig M Kessler
Department of Laboratory Medicine, Georgetown University, Washington, DC, USA
Thromb Haemost 102:15-24. 2009..Well-designed and adequately powered clinical trials should be conducted to indicate whether human thrombin products would improve the risk-benefit and cost-benefit profiles for surgeries complicated by excessive bleeding...
- The link between cancer and venous thromboembolism: a reviewCraig M Kessler
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
Am J Clin Oncol 32:S3-7. 2009..VTE continues to pose a substantial risk to patients with cancer because of a variety of tumor-, host-, and therapy-related factors...
- The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover studyCraig M Kessler
Hemophilia and Thrombophilia Comprehensive Treatment Center, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007, USA
Thromb Haemost 106:279-88. 2011..The PK profile of Wilate, combined with the 1:1 VWF/FVIII ratio, theoretically should facilitate dosing and laboratory monitoring of VWF replacement to prevent bleeding in individuals with VWD...
- B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover studyC M Kessler
Georgetown University Medical Center, Washington, DC 20007 2197, USA
Haemophilia 11:84-91. 2005..BDDrFVIII (ReFacto) has been developed with the additional benefit of being formulated without human albumin...
- Antidotes to haemorrhage: recombinant factor VIIaCraig M Kessler
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road, NW, Washington, DC 20007, USA
Best Pract Res Clin Haematol 17:183-97. 2004..Evidence-based data are necessary to establish the cost-benefit and risk-benefit profiles of rFVIIa, and to establish it as a standard treatment for bleeding...
- Current and future challenges of antithrombotic agents and anticoagulants: Strategies for reversal of hemorrhagic complicationsCraig M Kessler
Department of Medicine, Georgetown University of Medicine, Washington, DC 20007, USA
Semin Hematol 41:44-50. 2004....
- Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrateKashif Firozvi
Division of Hematology Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
Am J Hematol 81:582-9. 2006....
- Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrateRuby Anne E Deveras
Division of Hematology and Oncology, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2197, USA
Ann Intern Med 137:884-8. 2002..Safe and rapid reversal of excessive anticoagulation is occasionally needed to treat or avoid hemorrhagic complications...
- Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical useSlawomir Sobieszczyk
Division of Hematology Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
Acta Obstet Gynecol Scand 85:1239-47. 2006..Anecdotal experiences in the empirical use of this agent are described and dosing regimens, effects on bleeding, and safety data are presented...
- The pivotal role of thrombin in cancer biology and tumorigenesisKristen M Snyder
Divisions of Pediatric and Adult Hematology Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
Semin Thromb Hemost 34:734-41. 2008....
- Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvementEkatherine Asatiani
Georgetown University Hospital, Departments of Oncology and Medicine, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
Am J Hematol 77:144-6. 2004..0007). Prevalence of monoclonal gammopathy is higher than previously recognized and indicates advanced disease. However, the prognostic significance of the presence of monoclonal gammopathy in this population is unknown...
- D-dimer testing: the role of the clinical laboratory in the diagnosis of pulmonary embolismB H Mavromatis
Division of Hematology Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
J Clin Pathol 54:664-8. 2001..D-dimer measurements are very sensitive in excluding a diagnosis of pulmonary embolism in the setting of normal values, a low clinical suspicion, and non-diagnostic lung scans. Several assays have been developed and are reviewed...
- Propensity for hemorrhage and thrombosis in chronic myeloproliferative disordersCraig M Kessler
Vincent T Lombardi Cancer Center, MedStar Georgetown Medical Center, Washington, DC 20007 2197, USA
Semin Hematol 41:10-4. 2004..The role of leukocytosis in bleeding or hemorrhage in this population remains to be elucidated...
- Advances in the treatment of hemophiliaCraig M Kessler
Department of Medicine and Pathology, Division of Hematology Oncology, Clinical Coagulation Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
Clin Adv Hematol Oncol 6:184-7. 2008
- The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia AJ M Lusher
Division of Hematology and Oncology, Children s Hospital of Michigan, Detroit, MI 48201, USA
Haemophilia 9:38-49. 2003..B-domain-deleted recombinant factor VIII (BDDrFVIII) was developed when the B-domain was found to be redundant for maintaining haemostasis. This allows formulation of the final product without albumin added as a stabilizer...
- Microvascular free flap failure caused by unrecognized hypercoagulabilitySteven P Davison
Department of Plastic Surgery, Division of Coagulation, Georgetown University Hospital, Washington, DC, USA
Plast Reconstr Surg 124:490-5. 2009..However, despite technical and patient-selection advances, some components of free flap failure might be attributable to undiagnosed patient factors...
- Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolismPaul M Ridker
Center for Cardiovascular Disease Prevention and the Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston 02215, USA
N Engl J Med 348:1425-34. 2003..0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable benefit-to-risk ratio...
- End-stage liver disease in persons with hemophilia and transfusion-associated infectionsJames J Goedert
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
Blood 100:1584-9. 2002..04-fold (95% CI, 1.03-1.06) per year of age. Thus, HIV is associated with a markedly increased risk of HCV-related ESLD for persons with hemophilia, particularly with HBV infection, low CD4(+) lymphocytes, or older age...
- Antithrombin, heparin, and heparan sulfateSteven M Opal
Infectious Disease Division, Brown Medical School, Providence, RI 02860, USA
Crit Care Med 30:S325-31. 2002..The interaction between antithrombin and specific polysulfated, acidic oligosaccharide moieties found on heparin and related proteoglycan molecules within the circulation and on endothelial surfaces will also be examined...
- Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day periodSteven R Deitcher
Section of Hematology and Coagulation Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Clin Appl Thromb Hemost 12:389-96. 2006..Enoxaparin treatment was feasible, generally well tolerated, and effective for a 180-day period in the secondary prevention of venous thromboembolic events in patients with active malignancy...
- Fibrinolytic markers and vasodilatory capacity following acute exercise among men of differing training statusTracy Baynard
Department of Exercise Science, Syracuse University, Syracuse, NY, USA
Eur J Appl Physiol 101:595-602. 2007..These findings demonstrate that in healthy young men different physical activity patterns do not appear to impact the exercise-induced changes in fibrinolysis or vasodilatory capacity...